Shield Therapeutics

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

Healthcare |
Flash note

11.01.24

Shield Therapeutics — New CFO to support US traction

Healthcare |
Flash note

08.12.23

Shield Therapeutics — Delivering what the doctor ordered

Healthcare |
Update

29.09.23

Shield Therapeutics — Ramped up and heading into a stronger H223

Healthcare |
Update

04.05.23

Shield Therapeutics — FY23 a key year for business traction

Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (US$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(37.6)	(79.1)	(73.3)
Relative	(39.7)	(79.9)	(74.1)
52 week high/low	12.5p/1.6p

Financials

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.